From Breakthroughs Blog: FDA

 
Research Roundup: genetic protection against malaria, the vaccine pipeline, and counterfeit drugs and the FDA

A new study conducted by the Malaria Genomic Epidemiology Network (MalariaGEN)—a community of researchers across malaria-endemic regions—reveals a formerly unknown genetic variations that make people less susceptible to malaria.

Read More
PATH/Evelyn Hockstin
Research Roundup: a promising Ebola treatment, access to drugs for NCDs, a new approach to treating a deadly bacterium, and the perception of breakthrough drugs

The US Department of Health and Human Services (HHS) is partnering with New York–based Regeneron Pharmaceuticals, Inc. for the development of an Ebola treatment.

Read More
PATH/James Gathaney
Research Roundup: antibiotic and reproductive health R&D, leadership at the FDA, and a potential new strain of dengue fever.

The US Department of Health and Human Services (HHS) announced last week a partnership with pharmaceutical company AstraZeneca for the research and development (R&D) of antibiotics.

Read More
PATH/Aaron Joel Santos
Research Roundup: priority review vouchers, diagnosing drug resistance, and oral and universal flu vaccines

Pharmaceutical company AbbVie is paying United Therapeutics US$350 million for its priority review voucher (PRV)—which expedites the US Food and Drug Administration’s (FDA) review of a product by four months—and EP Vantage speculates on their motive.

Read More
Research Roundup: 3D-printed drugs, R&D in emergency settings, a universal flu vaccine, and more

The US Food and Drug Administration (FDA) approved the first 3D-printed drug last week, paving the way for the technology to be used to customize medical care to individual patients.

Read More
Research Roundup: a dengue vaccine, a breakthrough HIV treatment, antimicrobial R&D, and more

Later this year, French pharmaceutical company Sanofi plans to launch a vaccine for dengue fever, the first on the market for an infection for which nearly half of the world’s population is at risk.

Read More
Research Roundup: Drug-resistant TB, regulatory reform in India, a malaria vaccine, and more

A new study published in PLOS Medicine indicates that multi-drug resistant tuberculosis (TB) is less contagious than drug-susceptible TB.

Read More
PATH/Gabe Bienczycki
Research Roundup: India to expand list of essential medicines, China’s emerging leadership in the pharmaceutical industry, WHO paves the way for hepatitis C generics, and more

India is expected to add all of the drugs currently used in the government’s HIV/AIDS and tuberculosis (TB) control programs to its list of essential medicines within the next six months.

Read More
PATH/Heng Chivoan
Research Roundup: Intellectual property awards, FDA priorities, Australia R&D, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
PATH/Satvir Malhotra
Research Roundup: R&D in the post-2015 agenda, TB vaccines, the Global Innovation Fund, intellectual property, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
PATH/Dan Chang
Research Roundup: Funding global health R&D, the neglected disease pipeline, Ebola vaccines, FDA approvals, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
New tool to understand global health regulatory requirements

In this guest post, Tricia Aung—the GHTC’s regulatory associate—writes about a new database that provides easy access to information on global health regulatory information.

GHTC
Read More